Introduction
A certain percentage of leukemia/lymphoma patients relapse even after receiving powerful combined treatment of chemotherapy and/or radiotherapy followed by allogeneic bone marrow transplantation. The mechanisms of obtaining drug or radiation resistance and the behavior of so-called minimal residual leukemia/ lymphoma cells leading to relapse have been under intensive investigation. It is thought that a novel selective therapeutic strategy, eradication of leukemia/lymphoma cells in a cell-specific manner without affecting normal cells, will cure these refractory hematological malignancies. Recently, the presence of T cells capable of recognizing autologous leukemia cells in a patient with CML has been suggested. 1 Thus, the development of immunological methods for induction of T cells specific for hematopoietic tumors or stimulation of the antileukemia/ lymphoma functions is expected. Immunoprotection gene therapy may enhance host immunity against regrowth of leukemia/lymphoma cells through the administration of gene-modified autologous leukemia/ lymphoma cells. Recent mouse studies, mainly using solid tumor models, have shown that the transduction of cDNAs encoding cytokines [2] [3] [4] [5] or costimulatory molecules 6, 7 into tumor cells helped to decrease the tumorigenicity of the cells or endowed them with in vivo vaccination efficacy. Since differences in immunological properties between hematopoietic malignant cells and solid tumor cells was suggested, 8 it may be worthwhile to examine the propriety of adopting immuno/gene therapeutic approaches to leukemia/lymphoma therapy.
GM-CSF has recently been demonstrated to activate professional antigen-presenting cells (APC), such as dendritic cells (DC), by up-regulating their migration, maturation, antigen capturing, processing and presenting pathways [9] [10] [11] [12] and enhancing the surface expression of costimulatory molecules, such as B7 family molecules. 13 Thus antigens addressed to APC in the presence of GM-CSF, especially under locally concentrated conditions, are considered to stimulate effectively the proliferation of antigen-specific helper T lymphocytes and the subsequent expansion of antitumor effector cells. In this context, GM-CSF gene-transduced tumor cells are expected to make the immune system recognize the locally presented tumor antigens efficiently and stimulate the systemic antitumor immune response in vivo. In fact, Dranoff et al 14 clearly demonstrated that GM-CSF genetransduced murine B16 melanoma cells stimulated sys-temic antimelanoma immunity and that GM-CSF was the most potent molecule in a number of cytokines or adhesion molecules to be utilized in tumor vaccination experiments. Unfortunately, few reports describe the in vivo efficacy of antitumor immunity induced by GM-CSF transduced tumor cells. [14] [15] [16] CD80 (B7, B7-1) is a member of the B7 family of costimulatory molecules that are expressed on professional APCs. While the binding of T cell receptor (TCR) and antigen/MHC complex is essential for T cell activation, without costimulatory signaling generated by the binding of CD28 and B7 family molecules, T cells cannot be fully activated. Because most tumors lack expression of these costimulatory molecules on the surface membrane, it is believed that the tumor-recognizing T cell repertoire cannot be expanded to generate sufficient antitumor immune response, even if the tumor cells present antigen via MHC molecules. Based on this background, there have been many reports referring to successful induction of antitumor immunity using CD80 gene transduced tumor cells, [17] [18] [19] [20] [21] [22] [23] including leukemia/ lymphoma cells. 24, 25 Furthermore, the interest in using CD80 coupled with cytokine gene transduction has been increasing. Cayeux et al 26, 27 have demonstrated that tumor cells expressed interleukin-4 (IL-4) or IL-7, and CD80 induced more potent antitumor responses compared with single gene transfectants, but they also reported that vaccination effects shown by gene-modified tumor cells were abrogated when the cells were irradiated. Also, IL-2 28 or IL-12 29 were shown to cooperate with the CD80 molecule. As noted above, GM-CSF-transduced tumor cells are predicted to interact with helper T lymphocytes through APC-mediated, indirect pathways and CD80-transduced tumor cells are predicted to interact with cytotoxic T lymphocytes through direct pathways. We speculated that GM-CSF-and CD80-transduced cells stimulate host antitumor immune response via different pathways and will additionally induce efficient antitumor immune response when administered together in vivo.
For the purpose of enhancing the host's immunity against minimal residual leukemia/lymphoma, we evaluated the effects of gene transduction of GM-CSF or CD80 cDNA in mouse leukemia/lymphoma cells in inducing antitumor immunity in syngeneic host mouse, and further examined cooperative effects of both genes. and that of CD80/WEHI/1.8 cells was mediated partly by T cells and partly by NK cells.
Results

In vivo vaccination efficacy of gene-transduced WEHI 3B cells in syngeneic mice
As shown in Table 1 (Table 1) . We did not observe any additional vaccine effect of irradiated CD80-transduced cells as compared with irradiated wild-type WEHI 3B cells, which showed a significant protective vaccine effect. The vaccination with GMCSF/WEHI/3.2 cells, however, gave best protection against the challenged wild-type cells. These results indicated that the GM-CSF gene-transduced WEHI 3B cells enhanced in vivo protective immunity whether they were live or not and that live CD80-transduced WEHI 3B cells also enhanced protective immunity though irradiation reduced this enhancement.
In vivo efficacy of gene-transduced EL-4 cells in syngeneic mice
To see whether the results obtained above in WEHI 3B model were compatible with those in other hematopoietic tumor models, we examined the in vivo efficacy of GM-CSF-or CD80 gene-transduced EL-4 cells in syngeneic C57BL/6 mice.
Three groups of syngeneic C57BL/6 mice (10 mice per group) were inoculated s.c. into the right flank region with 3 × 10 5 cells of wild-type EL-4, GMCSF/EL-4 or CD80/EL-4. As shown in Figure 5 , compared with the wild-type control group, the survival periods were elongated slightly in the GMCSF/EL-4 cell-inoculated group and significantly in the the CD80/EL-4 cell-inoculated group. Thus, the gene transduction inhibited the original tumorigenicity of EL-4 cells. 
Cooperative enhancement of protective immunity with GM-CSF and CD80 gene-transduced EL-4 cells in syngeneic mice
We first studied the effect of combined expression of GM-CSF and CD80 gene-transduced WEHI 3B cells in syngeneic mice. As the irradiated WEHI 3B cells had their own immunogenicity in BALB/c mice in our experimental settings, irradiated GM-CSF-transduced WEHI 3B cells showed almost complete vaccine effects and further combined expression of CD80 showed the same complete vaccine effects (data not shown).
Next, the cooperative efficacy of GM-CSF-and CD80 gene-transduced vaccine cells was examined using EL-4 cells in C57BL/6 mice. To adjust strictly the amount of transgene product to the same level in each group, the combination effect was examined by a mixture of two of the following cell types: lethally irradiated EL-4, GMCSF/EL-4 or CD80/EL-4 (2.5 × 10 Number of surviving mice at 100 days after challenge was presented.
Figure 5 Tumorigenicity of gene transduced EL-4 cells in syngeneic hosts. Groups of 10 mice were inoculated with EL-4 (ć), GMCSF/EL-4 (̅) and CD80/EL-4 () cells (3 × 10
5 each) in right flank s.c. on day 0. The survivals were followed. All survivors at day 60 were tumor-free.
Figure 6 In vivo vaccination efficacy of irradiated, gene-transduced EL-4 cells in syngeneic mice. Groups of eight mice were vaccinated with HBSS (dotted line) or 50 Gy irradiated EL-4 (ć), GMCSF/EL-4 (̅) or CD80/EL-4 () cells (5 × 10 6 each). Fourteen days later (day 0), the mice were inoculated with 3 × 10
5 of wild-type EL-4 cells. The survivals were followed.
Figure 7 Cooperative enhancement of protective immunity with GM-CSF and CD80 gene-transduced EL-4 cells in syngeneic mice. Groups of eight mice were vaccinated with 50 Gy irradiated cells. The composition of the vaccine cells was as follows. As a negative control, 5 × 10 6 of wild-type EL-4 cells (ć) were injected. To adjust the transgene products, 2.5 × 10
6
EL-4 cells were combined with 2.5 × 10 6 each of GMCSF/EL-4 (̅) or CD80/EL-4 () cells, and 2.5 × 10 6 GMCSF/EL-4 cells were combined with 2.5 × 10 6 CD80/EL-4 cells (̆) and injected. Fourteen days later (day 0), all mice received an injection of 3 × 10
5 wild-type EL-4 cells. The survivals were followed. ized two independent experiments with similar results in Table 2 . These results indicated that the irradiated CD80-transduced cells provided immunoprotection when coinjected with GM-CSF-transduced cells, while vaccination with irradiated CD80-transduced cells alone did not.
Discussion
In this study, we examined the in vivo antitumor effects of GM-CSF-or CD80 (B7, B7-1) gene-transduced murine leukemia/lymphoma tumor cells. GM-CSF-or CD80 gene transduction abrogated tumorigenicity of WEHI 3B cells in syngeneic host mice. Irradiated, GM-CSF genetransduced WEHI 3B or EL-4 cells stimulated the vaccine effect against subsequent injection of the wild-type cells, but CD80 gene-transduced cells did not. Furthermore, GM-CSF-and CD80 gene-transduced EL-4 cells cooperatively enhanced the effect when irradiated and injected together.
The results that GM-CSF gene-transduced WEHI 3B (GMCSF/WEHI/3.2) cells were not tumorigenic in immunocompetent mice but tumorigenic in immunodeficient nude mice suggested that tumor rejection in immunocompetent mice is a thymic lymphocytedependent event. Although GM-CSF is known to stimulate innate (nonspecific) immunity mediated by neutrophils or macrophages, the GM-CSF secreting tumor cells might stimulate T cell-mediated (specific) immunity. Interesting results were obtained from the studies on tumorigenicity of CD80 gene-transduced WEHI 3B (CD80/WEHI/1.8) cells. Although the cells retained proliferative ability in vivo because they were completely tumorigenic in anti-Asialo GM 1 Ab-treated nude mice, they were not tumorigenic in immunocompetent mice and only partially tumorigenic in immunodeficient nude mice. These results suggested that the rejection of CD80/WEHI/1.8 cells in immunocompetent mice was dependent partly on T cells and partly on NK cells. Besides, we observed a remarkably reduced CD80-expressing cell population in the cells harvested from tumor which occasionally established in CD80/ WEHI/1.8 injected nude mice (data not shown). The results might be due to the selective growth of the CD80/WEHI/1.8 cells which lost CD80 expression by spontaneous silencing of the transferred gene. One possible explanation is the CD80 expression in WEHI 3B cells stimulated NK cytotoxicity in athymic nude mice. Most recently, Chambers et al 30 reported that the CD80 molecule stimulated the NK cells contributing to their cytotoxic activity in vitro. Our in vivo observation supports their in vitro findings.
In irradiated, whole cell vaccination experiments, we successfully demonstrated that the GM-CSF-transduced hematopoietic tumor cells could stimulate systemic antitumor responses in both WEHI 3B and EL-4 tumor models. While the vaccination of irradiated wild-type WEHI 3B cells induced a certain level of antitumor protection, the GM-CSF-transduced cells enhanced the level of the effect. The GM-CSF-gene transduction also effectively induced antitumor immunity in mice vaccinated with irradiated, whole cell EL-4 whose irradiated wild-type counterpart showed no protective effect. There have been a few reports on the in vivo induction of antitumor responses using GM-CSF-transduced tumor cells. [14] [15] [16] Dranoff et al 14 used a B16 melanoma model and showed that GM-CSF-transduced, irradiated whole cell vaccine induced the highest systemic antitumor immunity among 11 cytokine or adhesion molecule cDNAs examined. Most recently, Levitsky et al 16 in an A20 lymphoma model, showed that GM-CSF-transduced, irradiated whole cell vaccine primed idiotype-specific T cells and was effective in the treatment of established tumor, as well as the immunoprotection against wild-type assault. Furthermore, the results from clinical trials of GM-CSFgene transduced renal cell carcinoma and melanoma suggested the effectiveness of this vaccination method. 31, 32 Our results also strongly support the usefulness of GM-CSF gene-transduced and irradiated tumor vaccine cells. In paticular, GM-CSF-transduced cells could stimulate antitumor protective immunity even after they were lethally irradiated. In contrast, CD80-transduced tumor cells did not enhance immunity in WEHI 3B and EL-4 models. The injection of living CD80-transduced WEHI 3B cells stimulated immune protection against subsequent injection of wild-type cells, but the injection of irradiated CD80-transduced cells did not. In the EL-4 model, irradiated CD80-transduced EL-4 cells provided no protective effect as reported. 20, 22 In previous studies on hematopoietic tumor cells, Matulonis et al 24 showed similar results using BCR/ABL gene-transduced 32Dc13 cells. On the other hand, Dunussi-Joannopoulos et al 25 demonstrated that irradiated, CD80-transduced AML cells could have a therapeutic effect against pre-established tumor cells, as well as a vaccination effect. These discrepancies can be explained as follows: namely, cell line-specific character affected: (1) the amount and time course of the tumor antigen presented in vivo through the phagolytic processing of the injected cells; and (2) the efficiency of tumor antigen presentation in direct priming of CTL (cytotoxic T lymphocyte), because it is dependent on various factors (eg density of MHC/antigen complex or adherent molecules on the cell surface) as well as CD80 expression. Further study will be required for the clarification of the underlying mechanism.
Combined use of irradiated GM-CSF-and CD80-transduced cells remarkably enhanced antitumor immunity in the EL-4 tumor model. As discussed above, the vaccine effect was not enhanced by CD80 transduction alone, however CD80 transduction may induce some antitumor immunity in cooperation with GM-CSF. It is considered that the antitumor response induced by CD80-transduction is due to the direct priming of CTL in vivo. Some recent reports, however, suggested the participation of other mechanisms including the role of NK cells. CD80-transduced EL-4 cells were reported to be highly susceptible to lysis by NK cells in vitro 30 and, as noted above, our in vivo results supported this finding. Based on this background, we propose the following two mechanisms for the cooperation of GM-CSF-and CD80-transduced EL-4 cells. First, the cooperative antitumor response was generated through dual pathways, namely the APC-mediated pathway and the CTL-direct priming pathway triggered by GM-CSF and CD80 molecules, respectively. Second, the cooperation was generated by synergistic stimulation of the APC-mediated pathway by GM-CSF and other factors. Possible candidates for these factors include tumor antigens released from destroyed tumor cells or the cytokines which stimulate APC-mediated pathway synergistically with GM-CSF, both of which might be generated by NK cells through interaction with CD80-transduced tumor cells at the vaccination site. The combined use of GM-CSF-and CD80 gene-transduced tumor cells might prove a potent immuno/gene therapy for hematopoietic cancer, by enhancing the host's antitumor immunity against so-called minimal residual leukemia/lymphoma cells after conventional chemotherapy.
Materials and methods
Animals BALB/c, BALB/c (nu/nu) and C57BL/6 mice, 6-8-weekold females, were purchased from Nippon SLC (Hamamatsu, Japan). All mice were used in experiments at 8-12 weeks. All procedures using mice followed the Guide for Animal Experimentation, Institute of Medical Science, University of Tokyo.
Tumor cell lines
The WEHI 3B cell line 33 was a myelomonocytic leukemia line obtained from Dr D Metcalf (University of Melbourne). The EL-4 thymic lymphoma 34 was distributed from American Type Culture Collection (Rockville, MD, USA). Both WEHI 3B and EL-4 cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Life Technologies, Gaithersburg, MD, USA) supplemented with 10% fetal calf serum (FCS) and antibiotic/ antimycotic (Life Technologies) at 37°C, in 9% CO 2 .
Recombinant retroviral producer cell lines
The MFG-based retroviral vectors were used for GM-CSF and CD80 gene transduction. The ⌿CRIP-MFG murine GM-CSF cell line 14 was kindly provided by RC Mulligan. The ⌿CRIP cell line harboring murine CD80-geneinserted MFG vector was generated according to a method described elsewhere. 35 In brief, murine CD80 cDNA was cloned by reverse transcription (RT)-PCR. The cDNA was inserted to MFG vector which was transfected into ⌿CRIP packaging cell line using the calcium phosphate precipitation method. A clone producing a high titer of retrovirus was selected and designated as ⌿CRIP B7-10. These recombinant retroviral producer cell lines were maintained at 37°C, in 5% CO 2 in DMEM supplemented with 10% calf serum (Life Technologies) and antibiotic/antimycotic.
Gene transduction
Retroviral gene transduction was performed by the cocultivation method. Approximately 80% confluent producer cells were treated with mitomycin C (10 g/ml in culture medium) at 37°C, in 5% CO 2 for 2 h in order to prevent further cell division, and then WEHI 3B or EL-4 cells were cocultured on the producer cells for 5 days. Resulting GM-CSF gene-transduced WEHI 3B cells were designated as GMCSF/WEHI/3, and had a level of GM-CSF secretion of 42 ng per 24 h per 10 6 cells. Cells producing a high level of GM-CSF (388 ng per 24 h per 10 6 cells), GMCSF/WEHI/3.2 cells, were obtained from GMCSF/WEHI/3 by the limiting dilution method. The CD80 gene-transduced WEHI 3B cells were sorted by cell sorter (Epics Elite ESP, Coulter Electronics, Hialeah, FL, USA) using FITC-conjugated-anti-murine-CD80 monoclonal antibody (mAb) 1G10 (PharMingen, San Diego, CA, USA). Approximately 95% of the resulting cell population was CD80 positive, and designated as CD80/WEHI/1. The CD80 uniformly positive CD80/ WEHI/1.8 cells were isolated from CD80/WEHI/1 by the limiting dilution method. GM-CSF gene-transduced EL-4 cells, also generated through cocultivation with retroviral producer cells, were designated as GMCSF/EL-4, and had a level of GM-CSF secretion of 24 ng per 24 h per 10 6 cells. CD80 gene-transduced EL-4 cells, designated as CD80/EL-4, were obtained via retroviral gene transduction followed by condensation of CD80-positive cells using immunobeads. In brief, after retroviral transduction, cells were incubated with purified-rat antimurine CD80 mAb (1G10 (PharMingen) 1 g/ml) for 30 min on ice, washed three times with Hanks' balanced saline solution (HBSS; Life Technologies) containing 2% FCS, then further incubated with Dynabeads M-450 with sheep anti-rat IgG (Dynal, Oslo, Norway) for 5 min on ice. Separation procedures followed the manufacturer's recommendation.
ELISA (enzyme-linked immunosorbent assay) for murine GM-CSF Cells (1 × 10 5 cells/ml) were plated on a 90-mm petri dish in 10 ml of culture medium and incubated for 24 h. Culture supernatants were harvested and assessed for GM-CSF. The amount of secreted GM-CSF was determined by ELISA using mouse GM-CSF MiniKit (Endogen, Cambridge, MA, USA) according to the manufacturer's recommendation. Control samples were stained with appropriate fluorochrome conjugated Ig. The cells stained with biotin-conjugated and non-labeled mAb were visualized by staining with PE-streptavidin and FITC-conjugated anti-rat-Ig (PharMingen), respectively. Flow cytometry and data analysis were performed using a FACScan (Becton Dickinson Immunocytometry Systems, San José, CA, USA).
Monoclonal antibodies and FACS analysis
NK cell depletion in vivo NK cells in BALB/c nu/nu mice were depleted by intraperitoneal injection of rabbit anti-Asialo GM 1 anti-serum (0.2 ml of 1:20 diluted freeze-dried anti-serum; Wako, Osaka, Japan) 1 day before, and 7 and 14 days after tumor inoculation. Depletion of NK cells 7 days after first injection of anti-serum was confirmed by the absence of cytotoxic activity against YAC-1 cells (ATCC) in a standard 51 Cr release assay.
Tumorigenicity assay and vaccinations
Given numbers of WEHI 3B, EL-4, and their gene transduced cells were suspended in 0.5 ml of HBSS and injected subcutaneously (s.c.) into the flank of syngeneic mice. For vaccinations with irradiated cells, cultured cells received a lethal dose (50 Gy) of ␥-ray irradiation using Gammacell 40 (Atomic Energy of Canada, Ottawa, Canada) on ice and then were injected s.c. in the left flank as described above. Fourteen days after the inoculation with irradiated cells, an indicated number of unirradiated wild-type cells were injected s.c. in the right flank. The day of injection was designated as day 0. Cell suspensions used in all experiments contained over 90% viable cells as assessed by the trypan blue exclusion method. Tumor growth was monitored by palpation or calipers every 3 to 5 days. Survivals were followed until 100 days after the injection. In vivo experiments were repeated at least twice.
